A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application.
antineoplastic agents
clinical trial
cost analysis
drug acquisition
drug cost avoidance
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
03
2022
accepted:
17
05
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Oncology clinical trials can lead to relevant financial savings in drug acquisition for healthcare providers. Considerable methodological heterogeneity is observed among previous studies estimating these savings. We developed a methodology to estimate the economic benefit obtained from the enrollment of patients into clinical trials through the analysis of drug cost avoidance. We designed a decision algorithm to determine if a clinical trial is associated with drug cost avoidance. This algorithm is based on five scenarios according to the availability or not of standard treatment, the presence or absence of a control arm (placebo or active treatment), and the provider of the medication. We considered as reference the cost of the standard treatment that the patient would have received in routine clinical practice. We standardized drug doses and treatment durations according to the literature. Costs were considered from a National Health System perspective. We applied this methodology at a single, research-active University Hospital in 2019. A cost avoidance analysis per trial and patient was carried out on cancer patients. We analyzed 140 trials in which 198 patients were recruited. Drug cost avoidance was found in 120 trials (85.7%). The estimated total drug cost avoidance amounted to over €3,200,000. Melanoma and genitourinary tumors were the tumor types associated with the highest cost avoidance. The average drug cost avoidance per patient was €16,245. We describe a standardized method to estimate drug cost avoidance in clinical trials. We have applied it to all ongoing oncology clinical trials in our center. This methodology could be valuable for other centers to analyze the potential saving of clinical trials.
Sections du résumé
Background
UNASSIGNED
Oncology clinical trials can lead to relevant financial savings in drug acquisition for healthcare providers. Considerable methodological heterogeneity is observed among previous studies estimating these savings.
Methods
UNASSIGNED
We developed a methodology to estimate the economic benefit obtained from the enrollment of patients into clinical trials through the analysis of drug cost avoidance. We designed a decision algorithm to determine if a clinical trial is associated with drug cost avoidance. This algorithm is based on five scenarios according to the availability or not of standard treatment, the presence or absence of a control arm (placebo or active treatment), and the provider of the medication. We considered as reference the cost of the standard treatment that the patient would have received in routine clinical practice. We standardized drug doses and treatment durations according to the literature. Costs were considered from a National Health System perspective. We applied this methodology at a single, research-active University Hospital in 2019. A cost avoidance analysis per trial and patient was carried out on cancer patients.
Results
UNASSIGNED
We analyzed 140 trials in which 198 patients were recruited. Drug cost avoidance was found in 120 trials (85.7%). The estimated total drug cost avoidance amounted to over €3,200,000. Melanoma and genitourinary tumors were the tumor types associated with the highest cost avoidance. The average drug cost avoidance per patient was €16,245.
Conclusion
UNASSIGNED
We describe a standardized method to estimate drug cost avoidance in clinical trials. We have applied it to all ongoing oncology clinical trials in our center. This methodology could be valuable for other centers to analyze the potential saving of clinical trials.
Identifiants
pubmed: 35756684
doi: 10.3389/fonc.2022.889575
pmc: PMC9213877
doi:
Types de publication
Journal Article
Langues
eng
Pagination
889575Informations de copyright
Copyright © 2022 García-Sánchez, Collado-Borrell, González-Haba, Revuelta-Herrero, Escudero-Vilaplana, Marzal-Alfaro, Sánchez-Fresneda, Mur-Mur, Herranz, Martín and Sanjurjo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Transl Oncol. 2019 Jun;21(6):729-734
pubmed: 30414063
Am J Health Syst Pharm. 2018 Apr 15;75(8):561-573
pubmed: 29626006
J Oncol Pharm Pract. 2019 Jul;25(5):1099-1104
pubmed: 29792122
Fed Pract. 2016 Feb;33(Suppl 1):22S-25S
pubmed: 30766201
Br J Cancer. 2013 Oct 15;109(8):2051-7
pubmed: 24064969
Lung Cancer. 2013 Aug;81(2):236-40
pubmed: 23648072
Actas Urol Esp. 2015 Nov;39(9):553-7
pubmed: 26071987
BMC Health Serv Res. 2020 Nov 26;20(1):1089
pubmed: 33243262
Contemp Clin Trials. 2010 Nov;31(6):524-9
pubmed: 20840876
Am J Health Syst Pharm. 2000 Jan 1;57(1):40-3
pubmed: 10630555
BMJ Qual Saf. 2015 Oct;24(10):608-10
pubmed: 26038586
Trials. 2017 May 2;18(1):203
pubmed: 28464930
Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1304-1312
pubmed: 32522832
Am J Health Syst Pharm. 2004 Jan 1;61(1):27-32
pubmed: 14725117
Ann Oncol. 2011 Nov;22 Suppl 7:vii10-vii15
pubmed: 22039138
Contemp Clin Trials. 2011 Jul;32(4):485-91
pubmed: 21530679
Curr Oncol. 2016 Feb;23(Suppl 1):S7-S13
pubmed: 26985151